Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Challenge of immune-mediated adverse reactions in the emergency department.

Daniels GA, Guerrera AD, Katz D, Viets-Upchurch J.

Emerg Med J. 2019 Jun;36(6):369-377. doi: 10.1136/emermed-2018-208206. Epub 2019 May 21.

2.

Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.

Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R.

Cancer Immunol Res. 2019 Jun;7(6):866-873. doi: 10.1158/2326-6066.CIR-18-0716. Epub 2019 Apr 19.

PMID:
31003990
3.

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM.

J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004/jnccn.2019.0018.

PMID:
30959471
4.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.

Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF.

J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3.

5.

Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation.

Chang VA, Simpson DR, Daniels GA, Piccioni DE.

J Immunother Cancer. 2018 Dec 22;6(1):153. doi: 10.1186/s40425-018-0471-2.

6.

Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients.

Jensen TJ, Goodman AM, Kato S, Ellison CK, Daniels GA, Kim L, Nakashe P, McCarthy E, Mazloom AR, McLennan G, Grosu DS, Ehrich M, Kurzrock R.

Mol Cancer Ther. 2019 Feb;18(2):448-458. doi: 10.1158/1535-7163.MCT-18-0535. Epub 2018 Dec 6.

PMID:
30523049
7.

Adjuvant and Neoadjuvant Treatment of Skin Cancer.

Sacco AG, Daniels GA.

Facial Plast Surg Clin North Am. 2019 Feb;27(1):139-150. doi: 10.1016/j.fsc.2018.08.014. Review.

PMID:
30420067
8.

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.

Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS.

Cancer Discov. 2018 Oct;8(10):1250-1257. doi: 10.1158/2159-8290.CD-18-0280. Epub 2018 Aug 28.

PMID:
30154193
9.

Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Blitzblau R, Bowen GM, Contreras CM, Daniels GA, Decker R, Farma JM, Fisher K, Gastman B, Ghosh K, Grekin RC, Grossman K, Ho AL, Lewis KD, Loss M, Lydiatt DD, Messina J, Nehal KS, Nghiem P, Puzanov I, Schmults CD, Shaha AR, Thomas V, Xu YG, Zic JA, Hoffmann KG, Engh AM.

J Natl Compr Canc Netw. 2018 Jun;16(6):742-774. doi: 10.6004/jnccn.2018.0055.

PMID:
29891526
10.

Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.

Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP.

Oncologist. 2018 Oct;23(10):1236-1241. doi: 10.1634/theoncologist.2017-0375. Epub 2018 May 16.

PMID:
29769383
11.

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.

McDonald MA, Sanghvi P, Bykowski J, Daniels GA.

BMC Cancer. 2018 May 9;18(1):549. doi: 10.1186/s12885-018-4470-y. Review.

12.

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.

Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Oncoimmunology. 2017 Dec 22;7(3):e1404217. doi: 10.1080/2162402X.2017.1404217. eCollection 2018.

13.

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP.

J Immunother Cancer. 2017 Dec 19;5(1):102. doi: 10.1186/s40425-017-0307-5.

14.

Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.

Schwaederle M, Krishnamurthy N, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Patel SP, Parker BA, Kurzrock R.

Cancer. 2018 Mar 15;124(6):1288-1296. doi: 10.1002/cncr.31175. Epub 2017 Dec 6.

15.

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

Hallmeyer S, Gonzalez R, Lawson DH, Cranmer LD, Linette GP, Puzanov I, Taback B, Cowey CL, Ribas A, Daniels GA, Moore T, Gibney GT, Tawbi H, Whitman E, Lee G, Mun Y, Liu S, Hamid O.

Melanoma Res. 2017 Dec;27(6):585-590. doi: 10.1097/CMR.0000000000000398.

PMID:
29076950
16.

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.

Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R.

Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. doi: 10.1158/1078-0432.CCR-17-1439.

17.

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD.

J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.

PMID:
28915085
18.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

19.

Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma.

Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, Szalay AA.

Clin Cancer Res. 2017 Oct 1;23(19):5696-5702. doi: 10.1158/1078-0432.CCR-16-3232. Epub 2017 Jul 5.

20.

Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?

Ribero S, Stucci LS, Daniels GA, Borradori L.

Curr Opin Oncol. 2017 Mar;29(2):129-135. doi: 10.1097/CCO.0000000000000359. Review.

21.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

22.

Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.

Borradori L, Sutton B, Shayesteh P, Daniels GA.

Br J Dermatol. 2016 Dec;175(6):1382-1386. doi: 10.1111/bjd.14642. Epub 2016 Oct 17. No abstract available.

PMID:
27059424
23.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.

Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP.

Cancer Immunol Immunother. 2016 Dec;65(12):1533-1544. Epub 2016 Oct 6.

24.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF.

J Immunother Cancer. 2016 Sep 20;4:52. doi: 10.1186/s40425-016-0155-8. eCollection 2016.

25.

NCCN Guidelines Insights: Melanoma, Version 3.2016.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Aug;14(8):945-58.

PMID:
27496110
26.

Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Higgins SA, Ho AL, Lewis KD, Lydiatt DD, Nehal KS, Nghiem P, Olsen EA, Schmults CD, Sekulic A, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Wong SL, Zic JA, Hoffmann KG, Engh A.

J Natl Compr Canc Netw. 2016 May;14(5):574-97.

PMID:
27160235
27.

Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A.

J Natl Compr Canc Netw. 2016 Apr;14(4):450-73.

PMID:
27059193
28.

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12.

29.

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.

Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R.

Oncotarget. 2015 Oct 20;6(32):32602-9. doi: 10.18632/oncotarget.5289.

30.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS.

J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

PMID:
26014293
31.

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.

Schwaederle M, Daniels GA, Piccioni DE, Kesari S, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Cell Cycle. 2015;14(11):1730-7. doi: 10.1080/15384101.2015.1033596.

32.

On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.

Schwaederle M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Mol Cancer Ther. 2015 Jun;14(6):1488-94. doi: 10.1158/1535-7163.MCT-14-1061. Epub 2015 Apr 7.

33.

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.

Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R.

Cell Cycle. 2015;14(8):1252-9. doi: 10.1080/15384101.2015.1014149.

34.

Cyclin alterations in diverse cancers: Outcome and co-amplification network.

Schwaederlé M, Daniels GA, Piccioni DE, Fanta PT, Schwab RB, Shimabukuro KA, Parker BA, Kurzrock R.

Oncotarget. 2015 Feb 20;6(5):3033-42.

35.

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).

Kaufman HL, Wong MK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA.

J Pers Med. 2014 Mar 7;4(1):52-64. doi: 10.3390/jpm4010052.

36.

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes.

Wong MK, Kaufman HL, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA.

J Immunother Cancer. 2014 Jun 18;2:20. doi: 10.1186/2051-1426-2-20. eCollection 2014.

37.

Dermatofibrosarcoma protuberans, version 1.2014.

Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, McMillian N, Hoffman K, Ho M.

J Natl Compr Canc Netw. 2014 Jun;12(6):863-8.

PMID:
24925197
38.

Melanoma, version 4.2014.

Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 May;12(5):621-9.

PMID:
24812131
39.

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R.

Oncologist. 2014 Jun;19(6):631-6. doi: 10.1634/theoncologist.2013-0405. Epub 2014 May 5.

40.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

41.

Merkel cell carcinoma, version 1.2014.

Bichakjian CK, Olencki T, Alam M, Andersen JS, Berg D, Bowen GM, Cheney RT, Daniels GA, Glass LF, Grekin RC, Grossman K, Ho AL, Lewis KD, Lydiatt DD, Morrison WH, Nehal KS, Nelson KC, Nghiem P, Perlis CS, Shaha AR, Thorstad WL, Tuli M, Urist MM, Wang TS, Werchniak AE, Wong SL, Zic JA, Hoffmann KG, McMillian NR, Ho M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Mar 1;12(3):410-24.

PMID:
24616545
42.

Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells.

Ramsköld D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, Daniels GA, Khrebtukova I, Loring JF, Laurent LC, Schroth GP, Sandberg R.

Nat Biotechnol. 2012 Aug;30(8):777-82.

43.

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.

Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD.

Cancer Chemother Pharmacol. 2011 Aug;68(2):547-52. doi: 10.1007/s00280-011-1620-1. Epub 2011 Apr 24.

PMID:
21516509
44.

Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2.

Hayashi T, Chan M, Norton JT, Wu CC, Yao S, Cottam HB, Tawatao RI, Corr M, Carson DA, Daniels GA.

Melanoma Res. 2011 Feb;21(1):66-75. doi: 10.1097/CMR.0b013e328340ce6c.

45.

Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas.

Sanchez-Perez L, Kottke T, Daniels GA, Diaz RM, Thompson J, Pulido J, Melcher A, Vile RG.

J Immunol. 2006 Sep 15;177(6):4168-77.

46.

A simple method to cure established tumors by inflammatory killing of normal cells.

Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M, Gough M, Karim M, Bushell A, Chong H, Melcher A, Harrington K, Vile RG.

Nat Biotechnol. 2004 Sep;22(9):1125-32. Epub 2004 Aug 1.

47.

Advances in systemic therapy of small cell cancer of the lung.

Daniels GA, Adjei AA.

Expert Rev Anticancer Ther. 2001 Aug;1(2):211-21. Review.

PMID:
12113026
48.

Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex.

Daniels GA, Galanis E.

Curr Opin Mol Ther. 2001 Feb;3(1):70-6. Review.

PMID:
11249734
49.

Production of recombinant human type I procollagen trimers using a four-gene expression system in the yeast Saccharomyces cerevisiae.

Toman PD, Chisholm G, McMullin H, Giere LM, Olsen DR, Kovach RJ, Leigh SD, Fong BE, Chang R, Daniels GA, Berg RA, Hitzeman RA.

J Biol Chem. 2000 Jul 28;275(30):23303-9.

50.

Production of recombinant human type I procollagen homotrimer in the mammary gland of transgenic mice.

Toman PD, Pieper F, Sakai N, Karatzas C, Platenburg E, de Wit I, Samuel C, Dekker A, Daniels GA, Berg RA, Platenburg GJ.

Transgenic Res. 1999;8(6):415-27.

PMID:
10767986

Supplemental Content

Loading ...
Support Center